SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13G/A
(Amendment No. 1)
INFORMATION STATEMENT PURSUANT TO RULES13d-1 AND13d-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934
PROTAGONIST THERAPEUTICS, INC.
(Name of Issuer)
COMMON STOCK, $.00001 par value per share
(Title of Class of Securities)
74366E102
(CUSIP Number)
December 31, 2017
(Date of Event Which Requires Filing of This Statement)
Check the Appropriate box to designate the rule pursuant to which this schedule is filed:
☐ Rule 13d-1(b)
☐ Rule 13d-1(c)
☒ Rule 13d-1(d)
| CUSIP No. 74366E102 | 13G | Page 2 of 8 Pages |
| 1 | NAME OF REPORTING PERSONS S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
Pharmstandard International S.A. | |||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ☐ (b) ☐
| |||||
| 3 | SEC USE ONLY
| |||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
Luxembourg | |||||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER
0 | ||||
| 6 | SHARED VOTING POWER
982,270 | |||||
| 7 | SOLE DISPOSITIVE POWER
0 | |||||
| 8 | SHARED DISPOSITIVE POWER
982,270 | |||||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
982,270 | |||||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
☐ | |||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
4.8%*
*Based on 20,479,663 shares of the Issuer’s common stock outstanding as of October 31, 2017, as reported in the Issuer’s Form10-Q for the quarterly period ended October 31, 2017 and filed with the SEC on November 7, 2017. | |||||
| 12 | TYPE OF REPORTING PERSON*
CO | |||||
| CUSIP No. 74366E102 | 13G | Page 3 of 8 Pages |
| 1 | NAME OF REPORTING PERSONS S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
Joint Stock Company “Pharmstandard” | |||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ☐ (b) ☐
| |||||
| 3 | SEC USE ONLY
| |||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
Russian Federation | |||||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER
0 | ||||
| 6 | SHARED VOTING POWER
982,270 | |||||
| 7 | SOLE DISPOSITIVE POWER
0 | |||||
| 8 | SHARED DISPOSITIVE POWER
982,270 | |||||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
982,270 | |||||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
☐ | |||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
4.8%*
*Based on 20,479,663 shares of the Issuer’s common stock outstanding as of October 31, 2017, as reported in the Issuer’s Form10-Q for the quarterly period ended October 31, 2017 and filed with the SEC on November 7, 2017. | |||||
| 12 | TYPE OF REPORTING PERSON*
HC | |||||
| CUSIP No. 74366E102 | 13G | Page 4 of 8 Pages |
| Item 1 (a). | Name of Issuer: |
Protagonist Therapeutics, Inc.
| Item 1 (b). | Address of Issuer’s Principal Executive Offices: |
7707 Gateway Boulevard, Suite 140
Newark, California 94560-1160
| Item 2 (a). | Name of Person(s) Filing: |
Pharmstandard International S.A. (“Pharmstandard International”)
Joint Stock Company “Pharmstandard” (“Pharmstandard”)
A copy of the Joint Filing Agreement between the reporting persons, pursuant to which they agreed that this Schedule 13G/A would filed on behalf of each of them, is attached to the original Schedule 13G filed on February 13, 2017.
| Item 2 (b). | Address of Principal Business Office or, if None, Residence: |
Principal business office for Pharmstandard International:
10A rue Henri Schnadt
L-2530 Luxembourg
Principal business office for Pharmstandard:
Likhachevsky proezd 5 “B”, Moscow region,
Dogoprudny town, Russian Federation 141700
| Item 2 (c). | Citizenship: |
Pharmstandard International is a Luxembourg societe anonyme
Pharmstandard is a Russian joint stock company
| Item 2 (d). | Title of Class of Securities: |
Common Stock, $0.00001 par value per share.
| Item 2 (e). | CUSIP Number: |
74366E102
| Item 3. | If this statement is filed pursuant to Rules13d-1(b), or13d-2(b) or (c), check whether the person filing is a: |
| (a) | ☐ | Broker or dealer registered under Section 15 of the Act; | ||
| (b) | ☐ | Bank as defined in Section 3(a)(6) of the Act; | ||
| (c) | ☐ | Insurance Company as defined in Section 3(a)(19) of the Act; | ||
| (d) | ☐ | Investment Company registered under Section 8 of the Investment Company Act; | ||
| (e) | ☐ | Investment adviser in accordance with Rule13d-1(b)(1)(ii)(E); | ||
| CUSIP No. 74366E102 | 13G | Page 5 of 8 Pages |
| (f) | ☐ | Employee benefit plan or endowment plan in accordance with Rule 13d- 1(b)(1)(ii)(F); | ||
| (g) | ☐ | Parent holding company or control person, in accordance with Rule 13d- 1(b)(1)(ii)(G); | ||
| (h) | ☐ | A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act; | ||
| (i) | ☐ | A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940: | ||
| (j) | ☐ | Group, in accordance with Rule13d-1(b)(1)(ii)(j). | ||
| ☐ | If this statement is filed pursuant to Rule13d-1(c), check this box. | |||
| Item 4. | Ownership. |
| Provide the following information regarding the aggregate number and percentage of the class of securities identified in Item 1. |
| Pharmstandard International | Pharmstandard | |||||||
(a) Amount beneficially owned: | 982,270 | (1) | 982,270 | (1) | ||||
(b) Percent of class: | 4.8 | %(2) | 4.8 | %(2) | ||||
(c) Number of shares as to which such person has: | ||||||||
(i) Sole power to vote or to direct the vote: | ||||||||
(ii) Shared power to vote or to direct the vote: | 982,270 | (1) | 982,270 | (1) | ||||
(iii) Sole power to dispose or to direct the disposition of: | ||||||||
(iv) Shared power to dispose or to direct the disposition of: | 982,270 | (1) | 982,270 | (1) | ||||
| (1) | As of the date hereof Pharmstandard, as parent of Pharmstandard International, holds directly or indirectly a majority interest in the outstanding equity securities of Pharmstandard International and may therefore be deemed to beneficially own the shares covered by this Schedule 13G/A. |
| (2) | Based on 20,479,663 shares of the Issuer’s common stock outstanding as of October 31, 2017, as reported in the Issuer’s Form10-Q for the quarterly period ended October 31, 2017 and filed with the SEC on November 7, 2017. |
Instruction. For computations regarding securities which represent a right to acquire an underlying security, see Rule13d-3(d)(1).
| Item 5. | Ownership of Five Percent or Less of a Class. |
| If the statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒. |
| Item 6. | Ownership of More than Five Percent on Behalf of Another Person. |
N/A
| CUSIP No. 74366E102 | 13G | Page 6 of 8 Pages |
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company. |
N/A
| Item 8. | Identification and Classification of Members of the Group. |
N/A
| Item 9. | Notice of Dissolution of Group. |
N/A
| Item 10. | Certification. |
N/A
| CUSIP No. 74366E102 | 13G | Page 7 of 8 Pages |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
February 20, 2018 | ||
| (Date) | ||
| PHARMSTANDARD INTERNATIONAL S.A. | ||
| By: | /s/ Eriks Martinovskis | |
| Name: Eriks Martinovskis | ||
| Title: Director | ||
| CUSIP No. 74366E102 | 13G | Page 8 of 8 Pages |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
February 20, 2018 | ||
| (Date) | ||
| JOINT STOCK COMPANY “PHARMSTANDARD” | ||
| By: | /s/ Fedlyuk Victor P. | |
| Name: Fedlyuk Victor P. | ||
| Title: Deputy General Director for Legal Affairs | ||